Comparison of Taclorimus Ointment versus Kenalog in Ora Base for the Treatment of Oral Lichen Planus
DOI:
https://doi.org/10.70749/ijbr.v3i7.2329Keywords:
Tacrolimus, Triamcinolone Acetonide, Oral Lichen Planus, Randomized Controlled TrialAbstract
Background: Oral lichen planus (OLP) is a chronic, mucocutaneous condition that exhibits painful erosive or reticular lesions on the oral mucosa. Typically, treatment consists of topical corticosteroids (e.g. triamcinolone in Ora base. Tacrolimus, a calcineurin inhibitor, has been suggested as an effective substitute, especially among those that are steroid resistant; however, comparative clinical evidence is scarce. Objectives: The aim of the study was to examine and compare efficacy, safety of tacrolimus ointment and Kenalog in Ora base in patients with symptomatic oral lichen planus (OLP) for response, tolerability, and recurrence. Study Design: A prospective study. Place and duration of study: Department of Oral & Maxillofacial Surgery, Sandeman Provincial Hospital / Bolan Medical College / Hospital, Quetta, from February 2025 to May 2025. Methods: A randomized controlled prospective study clinical trial was performed on hundred patients with oral lichen planus symptomatology. Patients were randomized into 2 groups: Group A: tacrolimus 0.1% ointment and Group B triamcinolone acetonide (Kenalog) in Ora base both applied three times daily for six weeks. The outcome was measured by the severity of symptoms, decrease in the size of the lesions and side effects. Data analysis was done using SPSS v24. 0 to p < 0.05. Results: The mean age of 100 patients (52 males, 48 females) was 46.7 ± 11.2 years. There was significantly more improvement in pain reduction and resolution of lesion in Group A (tacrolimus) than with Group B (Kenalog). 40% in the tacrolimus group versus 22% in Kenalog. Partial response was observed in 46% vs 52%, respectively. Non-responders were 14% vs 26%. Burning upon application was more common with tacrolimus use and it was short lived. Mean decrease in clinical score was statistically significant overall (p = 0.003) for exercise plus tacrolimus treatment vs control. Conclusion: Tacrolimus ointment achieved better symptomatic improvement and higher remission than Kenalog in Ora base for patients with oral lichen planus. Transient burning was noted, however stopped spontaneously and the participant decided to continue. Kenalog in Ora base was effective but with lower rates of complete remission. It may be an effective and well-tolerated alternative in recalcitrant situations. Chronic studies are needed to confirm long-term efficacy and safety.
Downloads
References
1. Ali, W., Alam khan, S., Ullah Khan, F., Khan, S., Khan, W. A., Zafar, R., & Moqeet, M. A. (2023). Long-term clinical outcome of Tacrolimus skin ointment (0.03%) for the treatment of Vernal Keratoconjunctivitis: A quasi-experimental study. Cureus.
https://doi.org/10.7759/cureus.50579
2. Alshiyab, D., Al-qarqaz, F., Ba-shammakh, S., Al-Fakih, A., Altawalbeh, A., Alsheyab, S., Sarakbi, D., & Muhaidat, J. (2023). Comparison of the efficacy of tacrolimus 0.1% ointment vs calcipotriol/betamethasone in combination with NBUVB in treatment of vitiligo. Journal of Dermatological Treatment, 34(1).
https://doi.org/10.1080/09546634.2023.2252119
3. Alshiyab, D., Ba-shammakh, S. A., Al-Fakih, A., Tashman, O., Sarakbi, D., Al-qarqaz, F., Muhaidat, J., Atwan, A., & Cork, M. J. (2023). Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: A randomized controlled trial. Journal of Dermatological Treatment, 35(1).
https://doi.org/10.1080/09546634.2023.2296851
4. Alshiyab, D. M., Al-qarqaz, F. A., Muhaidat, J. M., Alkhader, Y. S., Al-sheyab, R. F., & Jafaar, S. I. (2020). Comparison of the efficacy of Tacrolimus 0.1% ointment and Tacrolimus 0.1% plus topical pseudocatalase/superoxide dismutase gel in children with limited vitiligo: A randomized controlled trial. Journal of Dermatological Treatment, 33(1), 146-149.
https://doi.org/10.1080/09546634.2020.1729952
5. Arnon, R., Rozen-Knisbacher, I., Yahalomi, T., Stanescu, N., Niazov, Y., Goldberg, D., Sharabi–Nov, A., & Mostovoy, D. (2022). When to start tacrolimus ointment for Vernal keratoconjunctivitis? A proposed treatment protocol. International Ophthalmology, 42(6), 1771-1780.
https://doi.org/10.1007/s10792-021-02174-5
6. Behera, B., Manoharan, P., Chandrashekar, L., & Gochhait, D. (2023). Papulonodular nonalopecic primary follicular mucinosis successfully treated with tacrolimus ointment. Indian Journal of Dermatology, Venereology and Leprology, 89, 751-754.
https://doi.org/10.25259/ijdvl_137_2022
7. Bernardes, L., Gil, J., Costa, E., Tavares, C., Rosa, A., Quadrado, M. J., & Murta, J. (2023). Topical tacrolimus in high-risk corneal transplants. European Journal of Ophthalmology, 34(1), 140-145.
https://doi.org/10.1177/11206721231172236
8. Cammarata, E., Lappi, A., Nicola, S., & Borrelli, P. (2021). Generalized granuloma annulare: Narrow-band UVB phototherapy combined with tacrolimus ointment. Dermatologic Therapy, 35(2).
https://doi.org/10.1111/dth.15250
9. Gao, W., Qiao, X., Zhu, J., Jin, X., & Wei, Y. (2021). Clinical Efficacy of Tacrolimus Ointment + 3% Boric Acid Lotion Joint Chinese Angelica Decoction in Chronic Perianal Eczema. Computational and Mathematical Methods in Medicine, 2021, 1-5.
https://doi.org/10.1155/2021/1016108
10. Gauthier, Y., Almasi-Nasrabadi, M., Cario-André, M., Pain, C., Rakhshan, A., & Ghalamkarpour, F. (2020). Tacrolimus (FK506) ointment combined with Nb-UVB could activate both hair follicle (HF) and dermal melanocyte precursors in vitiligo: The first histopathological and clinical study. Archives of Dermatological Research, 313(5), 383-388.
https://doi.org/10.1007/s00403-020-02068-z
11. Lott, P. W., Khaliddin, N., & Singh, S. (2020). Ointment tacrolimus for steroid resistant adenoviral nummular keratitis. The Medical Journal of Malaysia, 75(4), 461-463.
https://europepmc.org/article/med/32724020
12. Katoh, N., Ohya, Y., Ikeda, M., Ebihara, T., Katayama, I., Saeki, H., Shimojo, N., Tanaka, A., Nakahara, T., Nagao, M., Hide, M., Fujita, Y., Fujisawa, T., Futamura, M., Masuda, K., Murota, H., & Yamamoto-Hanada, K. (2020). Japanese guidelines for atopic dermatitis 2020. Allergology International, 69(3), 356-369.
https://doi.org/10.1016/j.alit.2020.02.006
13. Li, M., Tan, W., Du, J., Wang, Q., Wang, L., Lei, M., & Hao, P. (2020). Tacrolimus ointment in the treatment of hormone-dependent dermatitis. Medicine, 99(37), e22159.
https://doi.org/10.1097/md.0000000000022159
14. Liu, J., Shi, L., Wang, X., Wu, F., Hu, M., He, J., Lin, M., Wang, H., & Zhou, H. (2020). Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: A randomised controlled clinical trial and monitoring blood concentration. Journal of Oral Pathology & Medicine, 50(2), 251-259.
https://doi.org/10.1111/jop.13142
15. Liu, W., Pan, W., Zou, M., Jin, S., Mi, R., Cheng, G., & Piao, H. (2023). Tacrolimus and paclitaxel Co-loaded O/O ointment without surfactant: Synergistic combinations for the treatment of psoriasis. European Journal of Pharmaceutics and Biopharmaceutics, 185, 28-43.
https://doi.org/10.1016/j.ejpb.2023.02.007
16. Matsutani, M., Imai, Y., Inoue, Y., Nakatani‐Kusakabe, M., Natsuaki, M., Yamanishi, K., & Kanazawa, N. (2021). Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real‐world clinical practice. The Journal of Dermatology, 48(10), 1564-1568.
https://doi.org/10.1111/1346-8138.16039
17. Menezes, M. C., Buzelin, M., Nunes, C. B., & Alberti, L. R. (2021). Tacrolimus action pathways in an ointment base for hypertrophic scar prevention in a rabbit ear model. Anais Brasileiros de Dermatologia, 96(4), 429-435.
https://doi.org/10.1016/j.abd.2020.08.019
18. Ruggiero, A., Marasca, C., Villani, A., Fabbrocini, G., & Martora, F. (2022). Tacrolimus ointment may improve the effectiveness of adalimumab in patients with hidradenitis suppurativa: A novel promising treatment. Clinical and Experimental Dermatology, 47(10), 1871-1872.
https://doi.org/10.1111/ced.15299
19. Saha, B. C., Kumari, R., & Ambasta, A. (2023). Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with Vernal keratoconjunctivitis. Therapeutic Advances in Ophthalmology, 15.
https://doi.org/10.1177/25158414231173532
20. Sharjeel, M., Iqbal, U., Jabran, A., Mehmood, A., & Mohiuddin, M. (2022). Efficacy of single dose dermatological 0.1% tacrolimus ointment in the treatment of Vernal keratoconjunctivitis. Journal of the Pakistan Medical Association, 72(9), 1694-8.
https://doi.org/10.47391/jpma.3541
21. Spigariolo, C. B., Barei, F., Marzano, A. V., & Ferrucci, S. (2023). Abrupt Bullous cutaneous eruption after application of Tacrolimus ointment and sun exposure. Dermatology Practical & Conceptual, e2023164.
https://doi.org/10.5826/dpc.1303a164
22. Zhang, Q., Xu, P., Sun, C., Liu, L., & Jiang, W. (2020). Topical tacrolimus with different frequency for exfoliative cheilitis: A pilot study. Journal of Dermatological Treatment, 33(1), 550-554.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
